PL2376478T3 - Pirydyloksyindolowe inhibitory VEGF-R2 i ich zastosowania w leczeniu chorób - Google Patents
Pirydyloksyindolowe inhibitory VEGF-R2 i ich zastosowania w leczeniu choróbInfo
- Publication number
- PL2376478T3 PL2376478T3 PL09774876T PL09774876T PL2376478T3 PL 2376478 T3 PL2376478 T3 PL 2376478T3 PL 09774876 T PL09774876 T PL 09774876T PL 09774876 T PL09774876 T PL 09774876T PL 2376478 T3 PL2376478 T3 PL 2376478T3
- Authority
- PL
- Poland
- Prior art keywords
- pyridyloxyindoles
- vegf
- inhibitors
- disease
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20124308P | 2008-12-09 | 2008-12-09 | |
| US23334109P | 2009-08-12 | 2009-08-12 | |
| EP09774876.8A EP2376478B1 (en) | 2008-12-09 | 2009-12-07 | Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease |
| PCT/EP2009/066540 WO2010066684A2 (en) | 2008-12-09 | 2009-12-07 | Pyridyloxyindoles Inhibitors of VEGF-R2 and Use Thereof for Treatment of Disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2376478T3 true PL2376478T3 (pl) | 2017-10-31 |
Family
ID=42034535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL09774876T PL2376478T3 (pl) | 2008-12-09 | 2009-12-07 | Pirydyloksyindolowe inhibitory VEGF-R2 i ich zastosowania w leczeniu chorób |
Country Status (38)
| Country | Link |
|---|---|
| US (6) | US8242125B2 (pl) |
| EP (1) | EP2376478B1 (pl) |
| JP (1) | JP5580330B2 (pl) |
| KR (1) | KR101345956B1 (pl) |
| CN (2) | CN103193773B (pl) |
| AR (1) | AR074499A1 (pl) |
| AU (1) | AU2009326110B9 (pl) |
| CA (1) | CA2745922C (pl) |
| CL (1) | CL2011001378A1 (pl) |
| CO (1) | CO6382119A2 (pl) |
| CR (1) | CR20110270A (pl) |
| CU (1) | CU24097B1 (pl) |
| CY (1) | CY1119091T1 (pl) |
| DK (1) | DK2376478T3 (pl) |
| EA (1) | EA019681B1 (pl) |
| EC (1) | ECSP11011113A (pl) |
| ES (1) | ES2633959T3 (pl) |
| HN (1) | HN2011001593A (pl) |
| HR (1) | HRP20171075T1 (pl) |
| HU (1) | HUE035292T2 (pl) |
| IL (1) | IL213068A (pl) |
| JO (1) | JO3265B1 (pl) |
| LT (1) | LT2376478T (pl) |
| MX (1) | MX2011006093A (pl) |
| MY (1) | MY155649A (pl) |
| NZ (2) | NZ593030A (pl) |
| PE (1) | PE20110835A1 (pl) |
| PL (1) | PL2376478T3 (pl) |
| PT (1) | PT2376478T (pl) |
| RS (1) | RS56076B1 (pl) |
| SG (1) | SG171784A1 (pl) |
| SI (1) | SI2376478T1 (pl) |
| SV (1) | SV2011003939A (pl) |
| TN (1) | TN2011000263A1 (pl) |
| TW (1) | TWI429640B (pl) |
| UY (1) | UY32302A (pl) |
| WO (1) | WO2010066684A2 (pl) |
| ZA (1) | ZA201103759B (pl) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2738026C (en) | 2008-09-22 | 2017-01-24 | Array Biopharma Inc. | Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| MX2013004782A (es) * | 2010-10-27 | 2013-06-03 | Novartis Ag | Regimenes de dosificacion para el tratamiento de enfermedad vascular ocular. |
| CN102786469B (zh) * | 2011-05-18 | 2016-09-14 | 中国医学科学院药物研究所 | 邻吡啶酰肼衍生物及其制法和药物组合物与用途 |
| MX2014013428A (es) * | 2012-05-04 | 2015-02-04 | Novartis Ag | Moduladores de la ruta del complemento y usos de los mismos. |
| US9056874B2 (en) | 2012-05-04 | 2015-06-16 | Novartis Ag | Complement pathway modulators and uses thereof |
| KR101315227B1 (ko) * | 2012-05-30 | 2013-10-07 | 엘지디스플레이 주식회사 | 터치스크린 일체형 표시장치 및 그 구동 방법 |
| MX2014015738A (es) * | 2012-06-28 | 2015-08-06 | Novartis Ag | Derivados de pirrolidina y su uso como moduladores de la senda del complemento. |
| CN104619698B (zh) * | 2012-06-28 | 2016-08-31 | 诺华股份有限公司 | 吡咯烷衍生物及其作为补体途径调节剂的用途 |
| EP2867227B1 (en) * | 2012-06-28 | 2018-11-21 | Novartis AG | Complement pathway modulators and uses thereof |
| JP6273274B2 (ja) * | 2012-06-28 | 2018-01-31 | ノバルティス アーゲー | 補体経路モジュレーターおよびその使用 |
| US9464081B2 (en) * | 2012-06-28 | 2016-10-11 | Novartis Ag | Pyrrolidine derivatives and their use as complement pathway modulators |
| WO2014002053A1 (en) * | 2012-06-28 | 2014-01-03 | Novartis Ag | Pyrrolidine derivatives and their use as complement pathway modulators |
| BR112015000578A2 (pt) * | 2012-07-12 | 2017-06-27 | Novartis Ag | moduladores da via do complemento e usos dos mesmos |
| CN103570616B (zh) * | 2012-07-18 | 2017-10-20 | 中国医学科学院药物研究所 | N′‑直链烷酰基邻吡啶酰肼衍生物及其制法和药物组合物与用途 |
| CN105229003B (zh) | 2013-03-14 | 2017-03-15 | 诺华股份有限公司 | 作为补体因子b抑制剂用于治疗眼科疾病的2‑(1h‑吲哚‑4‑基甲基)‑3h‑咪唑并[4,5‑b]吡啶‑6‑甲腈衍生物 |
| WO2014154173A1 (zh) * | 2013-03-28 | 2014-10-02 | 广州康睿生物医药科技有限公司 | 一种抗血管新生化合物 |
| US20150018376A1 (en) * | 2013-05-17 | 2015-01-15 | Novartis Ag | Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof |
| US10174006B2 (en) * | 2013-06-06 | 2019-01-08 | Novartis Ag | Topical aqueous ophthalmic compositions containing a 1H-indole-1-carboxamide derivative and use thereof for treatment of ophthalmic disease |
| JO3425B1 (ar) | 2013-07-15 | 2019-10-20 | Novartis Ag | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b |
| JP6522502B2 (ja) | 2013-07-29 | 2019-05-29 | 協和発酵キリン株式会社 | Ｗｎｔシグナル阻害剤 |
| US9676728B2 (en) | 2013-10-30 | 2017-06-13 | Novartis Ag | 2-benzyl-benzimidazole complement factor B inhibitors and uses thereof |
| JP6248269B2 (ja) * | 2014-02-06 | 2017-12-20 | 株式会社Ｊｏｌｅｄ | 表示装置 |
| JP2017206437A (ja) * | 2014-08-18 | 2017-11-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ４−アミノピリジン誘導体 |
| CA2977764C (en) * | 2015-02-27 | 2021-11-09 | Nantbioscience, Inc. | Pyrimidine derivatives as kinase inhibitors and their therapeutical applications |
| WO2017003862A1 (en) * | 2015-07-01 | 2017-01-05 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
| EA035049B1 (ru) | 2015-07-16 | 2020-04-22 | Аррэй Байофарма Инк. | СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ |
| CN108697708A (zh) | 2015-10-26 | 2018-10-23 | 洛克索肿瘤学股份有限公司 | Trk抑制剂抗性癌症中的点突变以及与此相关的方法 |
| WO2017076932A1 (en) | 2015-11-06 | 2017-05-11 | F. Hoffmann-La Roche Ag | Indolin-2-one derivatives useful in the treatment of cns diseases |
| WO2017076931A1 (en) | 2015-11-06 | 2017-05-11 | F. Hoffmann-La Roche Ag | Indolin-2-one derivatives for use in the treatment of cns and related disorders |
| JP6857662B2 (ja) | 2015-11-06 | 2021-04-14 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | インドリン−２−オン誘導体 |
| CN108137561B (zh) | 2015-11-06 | 2021-03-26 | 豪夫迈·罗氏有限公司 | 二氢吲哚-2-酮衍生物 |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| TN2018000335A1 (en) | 2016-04-04 | 2020-01-16 | Loxo Oncology Inc | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| MA44612A (fr) | 2016-04-04 | 2019-02-13 | Loxo Oncology Inc | Méthodes de traitement de cancers pédiatriques |
| CN110049987B (zh) | 2016-05-18 | 2022-02-18 | 阵列生物制药公司 | 制备化合物及其盐的方法 |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| CN109789209A (zh) | 2016-10-14 | 2019-05-21 | 诺华股份有限公司 | 使用csf-1r抑制剂治疗眼部疾病的方法 |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| EP3571203B1 (en) | 2017-01-18 | 2023-06-07 | Array BioPharma Inc. | Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| JOP20190245A1 (ar) | 2017-04-20 | 2019-10-15 | Novartis Ag | أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| JP6997876B2 (ja) | 2018-01-18 | 2022-02-04 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての置換ピラゾリル［４，３－ｃ］ピリジン化合物 |
| TWI802635B (zh) | 2018-01-18 | 2023-05-21 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡咯并[2,3-d]嘧啶化合物 |
| US11524963B2 (en) | 2018-01-18 | 2022-12-13 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors |
| CN108586454B (zh) * | 2018-02-13 | 2021-02-26 | 沈阳药科大学 | 四氢吡啶并[4,3-d]嘧啶类衍生物及其用途 |
| CN110386892B (zh) * | 2018-04-16 | 2020-08-18 | 新发药业有限公司 | 一种4-氟-5-羟基-2-甲基-1h-吲哚的制备方法 |
| CN110483482A (zh) * | 2018-05-15 | 2019-11-22 | 北京诺诚健华医药科技有限公司 | 吲哚啉-1-甲酰胺类化合物、其制备方法及其在医药学上的应用 |
| CA3224949A1 (en) | 2018-07-31 | 2020-02-06 | Loxo Oncology, Inc. | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide |
| CA3111984A1 (en) | 2018-09-10 | 2020-03-19 | Array Biopharma Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
| EP3898626A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
| WO2020131674A1 (en) | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer |
| KR20220123023A (ko) | 2019-12-27 | 2022-09-05 | 슈뢰딩거, 인크. | 시클릭 화합물 및 이의 사용 방법 |
| EP4186894A4 (en) * | 2020-08-11 | 2024-01-17 | Henan Medinno Pharmaceutical Tech Co Ltd | FGFR INHIBITOR COMPOUND AND ITS USE |
| WO2022055963A1 (en) | 2020-09-10 | 2022-03-17 | Schrödinger, Inc. | Heterocyclic pericondensed cdc7 kinase inhibitors for the treatment of cancer |
| WO2022164789A1 (en) | 2021-01-26 | 2022-08-04 | Schrödinger, Inc. | Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disoders |
| TW202300150A (zh) | 2021-03-18 | 2023-01-01 | 美商薛定諤公司 | 環狀化合物及其使用方法 |
| WO2023139534A1 (en) | 2022-01-24 | 2023-07-27 | Novartis Ag | Spirocyclic piperidinyl derivatives as complement factor b inhibitors and uses thereof |
| TW202346279A (zh) | 2022-04-01 | 2023-12-01 | 瑞士商諾華公司 | 補體因子ｂ抑制劑及其用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE295365T1 (de) | 2000-02-09 | 2005-05-15 | Novartis Pharma Gmbh | Pyridinderivative als angiogenese- und/oder vegf- rezeptor-tyrosinkinase-inhibitoren |
| TWI304061B (en) * | 2000-10-20 | 2008-12-11 | Eisai R&D Man Co Ltd | Nitrogen-containing aromatic ring derivatives |
| GB0126902D0 (en) | 2001-11-08 | 2002-01-02 | Novartis Ag | Organic compounds |
| TW200406374A (en) * | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
| JP4183193B2 (ja) | 2002-08-30 | 2008-11-19 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 含窒素芳香環誘導体 |
| TW200418466A (en) | 2002-11-06 | 2004-10-01 | Smithkline Beecham Corp | Chemical compounds |
| SE0302324D0 (sv) | 2003-08-28 | 2003-08-28 | Astrazeneca Ab | Novel compounds |
| PE20060664A1 (es) | 2004-09-15 | 2006-08-04 | Novartis Ag | Amidas biciclicas como inhibidores de cinasa |
| GB0420520D0 (en) * | 2004-09-15 | 2004-10-20 | Novartis Ag | Organic compounds |
| GB0421525D0 (en) * | 2004-09-28 | 2004-10-27 | Novartis Ag | Inhibitors of protein kineses |
| DOP2006000051A (es) | 2005-02-24 | 2006-08-31 | Lilly Co Eli | Inhibidores de vegf-r2 y métodos |
| GT200600411A (es) * | 2005-09-13 | 2007-05-21 | Novartis Ag | Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular |
| BRPI0710496A2 (pt) | 2006-04-07 | 2011-08-16 | Novartis Ag | combinação que compreende a) composto de pirimidilaminobenzamida e b) inibidor de thr315iie cinase |
| CA2695989A1 (en) | 2007-08-10 | 2009-02-19 | Glaxosmithkline Llc | Certain nitrogen containing bicyclic chemical entities for treating viral infections |
| WO2009036066A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Vegfr inhibitors containing a zinc binding moiety |
| TWI440638B (zh) | 2007-10-30 | 2014-06-11 | Otsuka Pharma Co Ltd | 雜環化合物及其藥學組成物 |
-
2009
- 2009-12-06 JO JOP/2009/0466A patent/JO3265B1/ar active
- 2009-12-07 CU CU2011000129A patent/CU24097B1/es active IP Right Grant
- 2009-12-07 WO PCT/EP2009/066540 patent/WO2010066684A2/en active Application Filing
- 2009-12-07 US US12/632,396 patent/US8242125B2/en active Active
- 2009-12-07 SI SI200931684A patent/SI2376478T1/sl unknown
- 2009-12-07 AR ARP090104731A patent/AR074499A1/es unknown
- 2009-12-07 MX MX2011006093A patent/MX2011006093A/es active IP Right Grant
- 2009-12-07 DK DK09774876.8T patent/DK2376478T3/en active
- 2009-12-07 RS RS20170576A patent/RS56076B1/sr unknown
- 2009-12-07 EA EA201100873A patent/EA019681B1/ru not_active IP Right Cessation
- 2009-12-07 CN CN201310101393.0A patent/CN103193773B/zh active Active
- 2009-12-07 CN CN200980156323.7A patent/CN102307870B/zh active Active
- 2009-12-07 SG SG2011036878A patent/SG171784A1/en unknown
- 2009-12-07 NZ NZ593030A patent/NZ593030A/xx not_active IP Right Cessation
- 2009-12-07 MY MYPI2011002414A patent/MY155649A/en unknown
- 2009-12-07 PL PL09774876T patent/PL2376478T3/pl unknown
- 2009-12-07 EP EP09774876.8A patent/EP2376478B1/en active Active
- 2009-12-07 HU HUE09774876A patent/HUE035292T2/en unknown
- 2009-12-07 PT PT97748768T patent/PT2376478T/pt unknown
- 2009-12-07 NZ NZ601656A patent/NZ601656A/xx not_active IP Right Cessation
- 2009-12-07 CA CA2745922A patent/CA2745922C/en not_active Expired - Fee Related
- 2009-12-07 LT LTEP09774876.8T patent/LT2376478T/lt unknown
- 2009-12-07 PE PE2011001180A patent/PE20110835A1/es not_active Application Discontinuation
- 2009-12-07 ES ES09774876.8T patent/ES2633959T3/es active Active
- 2009-12-07 KR KR1020117015822A patent/KR101345956B1/ko active IP Right Grant
- 2009-12-07 UY UY0001032302A patent/UY32302A/es not_active Application Discontinuation
- 2009-12-07 AU AU2009326110A patent/AU2009326110B9/en not_active Ceased
- 2009-12-07 JP JP2011540046A patent/JP5580330B2/ja active Active
- 2009-12-08 TW TW098141904A patent/TWI429640B/zh not_active IP Right Cessation
-
2011
- 2011-05-23 CR CR20110270A patent/CR20110270A/es unknown
- 2011-05-23 ZA ZA2011/03759A patent/ZA201103759B/en unknown
- 2011-05-23 TN TN2011000263A patent/TN2011000263A1/fr unknown
- 2011-05-23 IL IL213068A patent/IL213068A/en not_active IP Right Cessation
- 2011-06-07 EC EC2011011113A patent/ECSP11011113A/es unknown
- 2011-06-08 CL CL2011001378A patent/CL2011001378A1/es unknown
- 2011-06-09 SV SV2011003939A patent/SV2011003939A/es unknown
- 2011-06-09 HN HN2011001593A patent/HN2011001593A/es unknown
- 2011-06-10 CO CO11072268A patent/CO6382119A2/es active IP Right Grant
-
2012
- 2012-06-05 US US13/488,760 patent/US8431584B2/en active Active
- 2012-09-13 US US13/613,062 patent/US8501756B2/en active Active
- 2012-09-13 US US13/613,019 patent/US8492393B2/en active Active
- 2012-09-13 US US13/613,053 patent/US8541432B2/en active Active
- 2012-09-13 US US13/613,034 patent/US8486954B2/en active Active
-
2017
- 2017-07-12 HR HRP20171075TT patent/HRP20171075T1/hr unknown
- 2017-07-19 CY CY20171100772T patent/CY1119091T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL213068A0 (en) | Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease | |
| HK1249446A1 (zh) | 用於治療乳糜瀉的組合物和方法 | |
| HRP20192282T8 (hr) | Inhibitori tfpi i postupci upotrebe | |
| HRP20181608T1 (hr) | Korištenje inhibitora pde7 u liječenju bolesti kretanja | |
| HK1173654A1 (zh) | 治療化合物及相關的使用方法 | |
| EP2334315A4 (en) | MEANS AND METHOD OF TREATMENT TREATMENT | |
| IL208354A0 (en) | Methods of treatment | |
| HK1169804A1 (zh) | 治療疼痛的方法 | |
| AP3272A (en) | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prosaglandin D2 mediated diseases | |
| EP2640395A4 (en) | TREATMENT OF DISEASES ASSOCIATED WITH SEARCH AND PULSE CONTROL BY PDE7 INHIBITORS | |
| IL207292A0 (en) | Use of ranolazine for treating pain | |
| EP2271352A4 (en) | COMPOSITIONS AND METHODS FOR TREATING NEOPLASTIC DISEASE | |
| EP2411006A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RENAL DISORDERS | |
| EP2509596A4 (en) | COMPOUNDS AND METHOD FOR THE TREATMENT OF EYE DISEASES | |
| GB0817859D0 (en) | Treatment of proteostatic disease | |
| GB0819543D0 (en) | Treatment of proteostatic disease | |
| GB0803515D0 (en) | Medicament and method of treatment |